Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial

  1. Ravassa, S.
  2. López, B.
  3. Ferreira, J.P.
  4. Girerd, N.
  5. Bozec, E.
  6. Pellicori, P.
  7. Mariottoni, B.
  8. Cosmi, F.
  9. Hazebroek, M.
  10. Verdonschot, J.A.J.
  11. Cuthbert, J.
  12. Petutschnigg, J.
  13. Moreno, M.U.
  14. Heymans, S.
  15. Staessen, J.A.
  16. Pieske, B.
  17. Edelmann, F.
  18. Clark, A.L.
  19. Cleland, J.G.F.
  20. Zannad, F.
  21. Díez, J.
  22. González, A.
Aldizkaria:
European Journal of Heart Failure

ISSN: 1879-0844,  1388-9842

Argitalpen urtea: 2022

Alea: 24

Zenbakia: 2

Orrialdeak: 321-331

Mota: Artikulua

DOI: 10.1002/EJHF.2394 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus